Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on The Estée Lauder Companies (EL – Research Report), PLBY Group (PLBY – Research Report) and Holley (HLLY – Research Report).
The Estée Lauder Companies (EL)
Canaccord Genuity analyst Susan Anderson maintained a Hold rating on The Estée Lauder Companies yesterday and set a price target of $140.00. The company’s shares closed last Wednesday at $145.04.
According to TipRanks.com, Anderson is a 5-star analyst with an average return of
The Estée Lauder Companies has an analyst consensus of Moderate Buy, with a price target consensus of $154.94, which is a 10.1% upside from current levels. In a report issued on March 22, DBS also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
PLBY Group (PLBY)
Canaccord Genuity analyst Jason Tilchen maintained a Buy rating on PLBY Group yesterday and set a price target of $4.00. The company’s shares closed last Wednesday at $0.97.
According to TipRanks.com, Tilchen is ranked #8102 out of 8772 analysts.
Currently, the analyst consensus on PLBY Group is a Moderate Buy with an average price target of $4.00.
Holley (HLLY)
In a report released yesterday, Brian McNamara from Canaccord Genuity maintained a Buy rating on Holley, with a price target of $8.00. The company’s shares closed last Wednesday at $4.45.
According to TipRanks.com, McNamara is a 4-star analyst with an average return of
Holley has an analyst consensus of Strong Buy, with a price target consensus of $8.40, representing a 95.8% upside. In a report released today, Benchmark Co. also maintained a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EL:
- Estee Lauder call volume above normal and directionally bullish
- Clinique named in carcinogen report to ‘damage brand perception,’ says Jefferies
- High Benzene Levels Found in Multiple Brands’ Acne Treatments
- Lab says chemical linked to cancer found in acne creams, Bloomberg reports
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls